The kinetics of minimal residual disease (MRD) and chimerism were studied in 15 patients
with chronic myeloid leukemia (CML) receiving nonmyeloablative stem cell transplantation …

Determining both lymphoid chimerism and the presence of minimal residual disease after
allogeneic bone marrow transplantation (BMT) for chronic myelogenous leukemia (CML) …

The detection of chimerism, residual molecular and cytogenetic disease following
transplantation of peripheral blood stem cells (PBSCT) with a nonmyeloablative conditioning …

Chronic myeloid leukaemia (CML) can be treated successfully with allogeneic bone marrow
transplantation (BMT) leading to long-term disease-free survival. Leukemia relapse …

Since graft-versus-leukemia (GVL) is the main weapon for disease eradication after reduced
intensity conditioning (RIC) allogeneic SCT, the availability of sensitive and specific …

We studied lineage-specific chimerism and minimal residual disease (MRD) in sequential
posttransplant samples from 55 patients who underwent unmanipulated (n= 44) or partially T …

Little data are available on the relative merits of chimerism and minimal residual disease
(MRD) monitoring for relapse prediction after allogeneic hematopoietic stem cell …

Reduced-intensity or nonmyeloablative stem cell transplantation (NST) is designed to
induce host-versus-graft tolerance by engraftment of donor stem cells. The rationale behind …

The primary rationale for autologous transplantation in chronic myelogenous leukemia
(CML) has been that benign stem cells capable of reconstituting hematopoiesis can be …

We evaluated the impact of detection of minimal residual disease by flow cytometry
(FCMRD) and CD3 chimerism in relapse in a cohort of 87 patients with acute myeloid …